AR104721A1 - Fragmento fab anti-ngf humano - Google Patents
Fragmento fab anti-ngf humanoInfo
- Publication number
- AR104721A1 AR104721A1 ARP160101483A ARP160101483A AR104721A1 AR 104721 A1 AR104721 A1 AR 104721A1 AR P160101483 A ARP160101483 A AR P160101483A AR P160101483 A ARP160101483 A AR P160101483A AR 104721 A1 AR104721 A1 AR 104721A1
- Authority
- AR
- Argentina
- Prior art keywords
- human fab
- seq
- amino acid
- acid sequence
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se provee un fragmento de anticuerpo Fab anti-NGF humano superior, que conservara una actividad de neutralización elevada, que presentara menos efectos secundarios como resultado de una exposición sistémica y que pudiera ejercer un efecto farmacológico local. El objetivo se logra mediante un fragmento de anticuerpo Fab-anti-NGF humano que comprende un fragmento de la cadena pesada que consiste en la secuencia de aminoácidos que se representa en SEQ ID Nº 5 y una cadena liviana que consiste en la secuencia de aminoácidos que se representa en SEQ ID Nº 8. Reivindicación 12: La composición farmacéutica de acuerdo con la reivindicación 11, caracterizada porque es una composición farmacéutica que puede ser administrada de manera local para tratar el dolor postoperatorio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015104806 | 2015-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104721A1 true AR104721A1 (es) | 2017-08-09 |
Family
ID=57393503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101483A AR104721A1 (es) | 2015-05-22 | 2016-05-20 | Fragmento fab anti-ngf humano |
Country Status (22)
Country | Link |
---|---|
US (1) | US11260124B2 (es) |
EP (1) | EP3299461B1 (es) |
JP (1) | JP6700620B2 (es) |
KR (1) | KR102440054B1 (es) |
CN (1) | CN107614683B (es) |
AR (1) | AR104721A1 (es) |
AU (1) | AU2016268625B2 (es) |
BR (1) | BR112017025029A2 (es) |
CA (1) | CA2986210C (es) |
CO (1) | CO2017012397A2 (es) |
HK (1) | HK1246349A1 (es) |
IL (1) | IL255832B (es) |
MA (1) | MA42138A (es) |
MX (1) | MX2017014911A (es) |
MY (1) | MY184164A (es) |
PH (1) | PH12017502126A1 (es) |
RU (1) | RU2729825C2 (es) |
SG (1) | SG11201709589XA (es) |
TW (1) | TWI706959B (es) |
UA (1) | UA123209C2 (es) |
WO (1) | WO2016190263A1 (es) |
ZA (1) | ZA201708169B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10725059B2 (en) * | 2015-04-06 | 2020-07-28 | Meso Scale Technologies, Llc. | High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus |
NL2017890B1 (nl) * | 2016-11-29 | 2018-06-11 | Josh Ip Iii B V | Medische transportinrichting, hulpaandrijving, en werkwijze voor het transporteren van een dergelijke transportinrichting |
US20210147529A1 (en) * | 2018-05-15 | 2021-05-20 | Astellas Pharma Inc. | Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527358A (en) | 1994-01-21 | 1996-06-18 | Medtronic, Inc. | Temporary medical electrical lead |
WO2004032852A2 (en) | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
PL215171B1 (pl) | 2002-12-24 | 2013-10-31 | Rinat Neuroscience Corp | Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd |
TWI385180B (zh) | 2003-07-15 | 2013-02-11 | Amgen Inc | 作為選擇性神經生長因子(ngf)通道抑制劑之人類抗-ngf中和抗體 |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
CA2562024C (en) * | 2004-04-07 | 2014-05-27 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
ES2435691T3 (es) | 2005-01-24 | 2013-12-23 | Medimmune Limited | Anticuerpos humanos contra NGF humano |
US9532943B2 (en) | 2010-12-20 | 2017-01-03 | Cormatrix Cardiovascular, Inc. | Drug eluting patch for the treatment of localized tissue disease or defect |
JP2007244601A (ja) | 2006-03-15 | 2007-09-27 | Kanazawa Univ | 心筋用パッド |
EP2572729A3 (en) | 2007-08-10 | 2013-06-05 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
SG10201703707YA (en) * | 2009-03-19 | 2017-06-29 | Chugai Pharmaceutical Co Ltd | Pharmaceutical formulation containing improved antibody molecules |
PE20121540A1 (es) | 2009-05-04 | 2012-12-22 | Abbott Res Bv | Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada |
BR112013015308A2 (pt) | 2010-12-20 | 2016-09-20 | Cormatrix Cardiovascular Inc | dispositivo para administrar um inibidor de hmg coa reductase ao tecido cardiovascular para tratar uma doença cardiovascular |
EP3498732B1 (en) * | 2011-05-06 | 2021-11-17 | Zoetis Services LLC | Anti-nerve growth factor antibodies and methods of preparing and using the same |
EP3502136A1 (en) * | 2011-05-06 | 2019-06-26 | Nexvet Australia Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
GB201114858D0 (en) * | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
DK2743348T3 (en) * | 2011-08-11 | 2018-02-26 | Astellas Pharma Inc | Hitherto UNKNOWN ANTI-HUMAN NGF ANTIBODY |
PE20150212A1 (es) | 2012-06-08 | 2015-02-27 | Glenmark Pharmaceuticals Sa | Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados |
JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトngf抗体 |
US9127055B2 (en) * | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
AU2015362775B2 (en) | 2014-12-17 | 2019-07-04 | Dow Global Technologies Llc | Viscoelastic polyurethane foam with aqueous polymer dispersion |
-
2016
- 2016-05-20 US US15/575,969 patent/US11260124B2/en active Active
- 2016-05-20 BR BR112017025029-2A patent/BR112017025029A2/pt active Search and Examination
- 2016-05-20 JP JP2017520694A patent/JP6700620B2/ja active Active
- 2016-05-20 SG SG11201709589XA patent/SG11201709589XA/en unknown
- 2016-05-20 MY MYPI2017704449A patent/MY184164A/en unknown
- 2016-05-20 EP EP16799968.9A patent/EP3299461B1/en active Active
- 2016-05-20 AR ARP160101483A patent/AR104721A1/es unknown
- 2016-05-20 AU AU2016268625A patent/AU2016268625B2/en active Active
- 2016-05-20 TW TW105115796A patent/TWI706959B/zh active
- 2016-05-20 RU RU2017145071A patent/RU2729825C2/ru active
- 2016-05-20 MX MX2017014911A patent/MX2017014911A/es unknown
- 2016-05-20 MA MA042138A patent/MA42138A/fr unknown
- 2016-05-20 KR KR1020177034038A patent/KR102440054B1/ko active IP Right Grant
- 2016-05-20 CA CA2986210A patent/CA2986210C/en active Active
- 2016-05-20 UA UAA201712706A patent/UA123209C2/uk unknown
- 2016-05-20 CN CN201680029680.7A patent/CN107614683B/zh active Active
- 2016-05-20 WO PCT/JP2016/065099 patent/WO2016190263A1/ja active Application Filing
-
2017
- 2017-11-21 IL IL255832A patent/IL255832B/en unknown
- 2017-11-22 PH PH12017502126A patent/PH12017502126A1/en unknown
- 2017-11-30 ZA ZA2017/08169A patent/ZA201708169B/en unknown
- 2017-11-30 CO CONC2017/0012397A patent/CO2017012397A2/es unknown
-
2018
- 2018-05-03 HK HK18105725.1A patent/HK1246349A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2016190263A1 (ja) | 2018-04-12 |
RU2017145071A (ru) | 2019-06-24 |
TW201713691A (zh) | 2017-04-16 |
CA2986210C (en) | 2022-04-26 |
ZA201708169B (en) | 2019-06-26 |
CN107614683B (zh) | 2020-12-22 |
HK1246349A1 (zh) | 2018-09-07 |
MX2017014911A (es) | 2018-03-23 |
UA123209C2 (uk) | 2021-03-03 |
IL255832B (en) | 2021-07-29 |
IL255832A (en) | 2018-01-31 |
AU2016268625A1 (en) | 2017-12-07 |
KR102440054B1 (ko) | 2022-09-06 |
US11260124B2 (en) | 2022-03-01 |
EP3299461A1 (en) | 2018-03-28 |
EP3299461B1 (en) | 2023-03-29 |
MA42138A (fr) | 2018-03-28 |
AU2016268625B2 (en) | 2022-01-27 |
CA2986210A1 (en) | 2016-12-01 |
KR20180006391A (ko) | 2018-01-17 |
US20180147281A1 (en) | 2018-05-31 |
RU2017145071A3 (es) | 2019-10-17 |
SG11201709589XA (en) | 2017-12-28 |
CN107614683A (zh) | 2018-01-19 |
MY184164A (en) | 2021-03-24 |
WO2016190263A1 (ja) | 2016-12-01 |
CO2017012397A2 (es) | 2018-02-28 |
BR112017025029A2 (pt) | 2018-08-07 |
TWI706959B (zh) | 2020-10-11 |
PH12017502126A1 (en) | 2018-05-07 |
RU2729825C2 (ru) | 2020-08-12 |
EP3299461A4 (en) | 2018-12-19 |
JP6700620B2 (ja) | 2020-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
ECSP21086530A (es) | Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable | |
AR107014A1 (es) | Formulación farmacéutica acuosa | |
CL2016000530A1 (es) | Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13). | |
BR112017023269A2 (pt) | métodos para tratamento de câncer | |
CY1123963T1 (el) | Καινοτομα πολυμερικα προφαρμακα hgh | |
PE20161390A1 (es) | Anticuerpos multiespecificos | |
BR112017018954A2 (pt) | uso de forma mutante de proteína ras e método para tratar câncer | |
DOP2017000035A (es) | Inhibidores de la proteina quinasa c y metodos de su uso | |
EA201791518A1 (ru) | Способы лечения заболеваний сетчатки | |
EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
CL2018000811A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
CO7141430A2 (es) | Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación | |
EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
CO2019003865A2 (es) | Proteína terapéutica | |
AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
AR104721A1 (es) | Fragmento fab anti-ngf humano | |
CO6280488A2 (es) | Combinacion farmaceutica | |
AR109799A1 (es) | Composición para el tratamiento del cabello | |
AR108790A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria | |
EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
CY1122708T1 (el) | Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου | |
EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение |